Abdul Razzak Alamir, MD
Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1841263662
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations.
Across 256 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BETA Bionics, Inc.$722
- Mannkind Corporation$349
- Novo Nordisk$339
- Sanofi-aventis U.S. LLC$332
- Boehringer Ingelheim$292
- Dexcom, Inc.$261
- plus $2K from 30 others
Across 3 payments — averaging $9851.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$15K
- Sanofi US Services Inc.$14K
What the payments were for
- Food & beverage$4,27395%
- Education$311%
- Gifts$1784%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BETA Bionics, Inc. | 58 | $722 |
| Mannkind Corporation | 14 | $349 |
| Novo Nordisk | 18 | $339 |
| Sanofi-aventis U.S. LLC | 23 | $332 |
| Boehringer Ingelheim | 18 | $292 |
| Dexcom, Inc. | 12 | $261 |
| Insulet Corporation | 12 | $230 |
| Lilly USA, LLC | 10 | $196 |
| Abbott | 11 | $194 |
| Bayer | 9 | $169 |
| Novartis | 8 | $165 |
| Amgen(2 entities) | 8 | $144 |
| Xeris Pharmaceuticals, Inc. | 7 | $142 |
| AbbVie | 7 | $129 |
| Medtronic(2 entities) | 5 | $87 |
| Cequr Corporation | 2 | $74 |
| Johnson & Johnson | 5 | $67 |
| Merck | 4 | $66 |
| Ascensia Diabetes Care US Inc. | 3 | $64 |
| Corcept Therapeutics | 3 | $59 |
| Sequel Med Tech, LLC | 1 | $48 |
| Lifescan, Inc. | 2 | $42 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| Recordati_rare_diseases_inc. | 2 | $40 |
| Astellas Pharma US Inc | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Verity Pharmaceuticals Inc. | 1 | $24 |
| IBSA Pharma Inc. | 1 | $22 |
| Pfizer | 1 | $21 |
| Senseonics, Incorporated | 1 | $21 |
| Intuity Medical Inc | 1 | $19 |
| Companion Medical, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Averitas Pharma Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $13 |
| Radius Health, Inc. | 1 | $13 |
How this compares
$4,482 in reported general payments places this provider in the 60th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 485 | $685,189 |
| MounjaroTirzepatide | 197 | $279,846 |
| JardianceEmpagliflozin | 205 | $240,804 |
| TrulicityDulaglutide | 137 | $207,842 |
| Tresiba Flextouch U-100Insulin Degludec | 179 | $118,807 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 104 | $76,624 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $55,593 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $53,189 |
| Novolog FlexpenInsulin Aspart | 160 | $51,405 |
| Humalog Kwikpen U-100Insulin Lispro | 150 | $48,950 |
| JanuviaSitagliptin Phosphate | 42 | $48,550 |
| TradjentaLinagliptin | 56 | $47,377 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 55 | $47,318 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 285 | $42,131 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 246 | $35,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $339 | $718,482536 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $196 | $496,397365 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $292 | $293,997274 claims |
| MerckJanuvia | $66 | $48,55042 claims |
| AbbVieSynthroid | $129 | $21,202235 claims |
| Johnson & JohnsonInvokana | $67 | $13,87117 claims |
| Sanofi-aventis U.S. LLCLantus, Admelog | $332 | $13,47651 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $40 | $8,261898 claims |
| IBSA Pharma Inc.Tirosint | $22 | $4,20330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Scottsdale
- Amir HarariScottsdale$361K
- Kristina BlohmScottsdale$220K
- Andrea FerencziScottsdale$132K
- Sreedevi ReddyScottsdale$28K
- Grace Zlaket MattaScottsdale$17K
- Heather SaranScottsdale$14K
- Chandana MishraScottsdale$11K
- Vincent LiouScottsdale$10K
- Kimberlee BrontsemaScottsdale$9K
- Dena HaddadScottsdale$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.